Addus HomeCare Corporation (ADUS)
USD 101.02
(0.02%)
USD 101.02
(0.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 317.73 Million USD | 4.36% |
| 2022 | 304.45 Million USD | -18.43% |
| 2021 | 373.24 Million USD | -0.18% |
| 2020 | 373.9 Million USD | 132.01% |
| 2019 | 161.15 Million USD | 101.81% |
| 2018 | 79.85 Million USD | -13.23% |
| 2017 | 92.03 Million USD | 27.64% |
| 2016 | 72.1 Million USD | 41.69% |
| 2015 | 50.88 Million USD | -3.71% |
| 2014 | 52.84 Million USD | 5.53% |
| 2013 | 50.07 Million USD | -9.67% |
| 2012 | 55.44 Million USD | -18.77% |
| 2011 | 68.25 Million USD | -13.42% |
| 2010 | 78.83 Million USD | -2.37% |
| 2009 | 80.74 Million USD | -20.19% |
| 2008 | 101.17 Million USD | 20.29% |
| 2007 | 84.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 288.85 Million USD | -9.09% |
| 2024 Q2 | 194.89 Million USD | -32.53% |
| 2024 Q3 | 205.26 Million USD | 5.32% |
| 2023 Q2 | 262.03 Million USD | -7.15% |
| 2023 Q3 | 351.39 Million USD | 34.1% |
| 2023 Q4 | 317.73 Million USD | -9.58% |
| 2023 FY | 317.73 Million USD | 4.36% |
| 2023 Q1 | 282.19 Million USD | -7.31% |
| 2022 Q3 | 331.09 Million USD | -9.23% |
| 2022 Q2 | 364.75 Million USD | -9.14% |
| 2022 FY | 304.45 Million USD | -18.43% |
| 2022 Q1 | 401.43 Million USD | 7.55% |
| 2022 Q4 | 304.45 Million USD | -8.05% |
| 2021 Q4 | 373.24 Million USD | 1.74% |
| 2021 Q3 | 366.86 Million USD | 6.31% |
| 2021 Q2 | 345.1 Million USD | -0.74% |
| 2021 Q1 | 347.66 Million USD | -7.02% |
| 2021 FY | 373.24 Million USD | -0.18% |
| 2020 Q4 | 373.9 Million USD | 99.07% |
| 2020 FY | 373.9 Million USD | 132.01% |
| 2020 Q1 | 158.01 Million USD | -1.95% |
| 2020 Q3 | 187.83 Million USD | 13.11% |
| 2020 Q2 | 166.06 Million USD | 5.09% |
| 2019 Q3 | 149.12 Million USD | 24.95% |
| 2019 Q2 | 119.34 Million USD | 22.66% |
| 2019 FY | 161.15 Million USD | 101.81% |
| 2019 Q1 | 97.29 Million USD | 21.84% |
| 2019 Q4 | 161.15 Million USD | 8.07% |
| 2018 Q4 | 79.85 Million USD | -51.0% |
| 2018 Q2 | 157.06 Million USD | 70.67% |
| 2018 Q1 | 92.03 Million USD | 0.0% |
| 2018 Q3 | 162.96 Million USD | 3.76% |
| 2018 FY | 79.85 Million USD | -13.23% |
| 2017 Q3 | 95.63 Million USD | 8.6% |
| 2017 FY | 92.03 Million USD | 27.64% |
| 2017 Q4 | 92.03 Million USD | -3.77% |
| 2017 Q2 | 88.05 Million USD | 18.84% |
| 2017 Q1 | 74.09 Million USD | 2.77% |
| 2016 FY | 72.1 Million USD | 41.69% |
| 2016 Q4 | 72.1 Million USD | -9.85% |
| 2016 Q2 | 94.58 Million USD | 8.93% |
| 2016 Q1 | 86.82 Million USD | 70.63% |
| 2016 Q3 | 79.97 Million USD | -15.44% |
| 2015 Q4 | 50.88 Million USD | -11.24% |
| 2015 FY | 50.88 Million USD | -3.71% |
| 2015 Q1 | 52.67 Million USD | -0.33% |
| 2015 Q3 | 57.33 Million USD | 6.98% |
| 2015 Q2 | 53.58 Million USD | 1.74% |
| 2014 Q1 | 45.99 Million USD | -8.15% |
| 2014 Q4 | 52.84 Million USD | 0.86% |
| 2014 Q2 | 45.65 Million USD | -0.75% |
| 2014 FY | 52.84 Million USD | 5.53% |
| 2014 Q3 | 52.39 Million USD | 14.77% |
| 2013 Q4 | 50.07 Million USD | 14.08% |
| 2013 Q3 | 43.89 Million USD | -2.21% |
| 2013 Q1 | 43.56 Million USD | -21.42% |
| 2013 Q2 | 44.88 Million USD | 3.03% |
| 2013 FY | 50.07 Million USD | -9.67% |
| 2012 FY | 55.44 Million USD | -18.77% |
| 2012 Q4 | 55.44 Million USD | -10.71% |
| 2012 Q3 | 62.09 Million USD | 0.41% |
| 2012 Q2 | 61.83 Million USD | -8.05% |
| 2012 Q1 | 67.24 Million USD | -1.47% |
| 2011 Q2 | 79.62 Million USD | 12.87% |
| 2011 Q3 | 74.87 Million USD | -5.97% |
| 2011 FY | 68.25 Million USD | -13.42% |
| 2011 Q4 | 68.25 Million USD | -8.84% |
| 2011 Q1 | 70.54 Million USD | -10.51% |
| 2010 Q1 | 84.09 Million USD | 4.15% |
| 2010 Q2 | 84.29 Million USD | 0.23% |
| 2010 FY | 78.83 Million USD | -2.37% |
| 2010 Q4 | 78.83 Million USD | -9.6% |
| 2010 Q3 | 87.2 Million USD | 3.46% |
| 2009 Q3 | 108.1 Million USD | -1.9% |
| 2009 FY | 80.74 Million USD | -20.19% |
| 2009 Q2 | 110.19 Million USD | 0.0% |
| 2009 Q4 | 80.74 Million USD | -25.3% |
| 2008 FY | 101.17 Million USD | 20.29% |
| 2008 Q4 | 101.17 Million USD | 0.0% |
| 2007 FY | 84.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 2.47 Billion USD | 87.143% |
| AirSculpt Technologies, Inc. | 129.56 Million USD | -145.239% |
| Amedisys, Inc. | 940.38 Million USD | 66.213% |
| American Oncology Network, Inc. | 368.72 Million USD | 13.83% |
| Astrana Health, Inc. | 522.59 Million USD | 39.201% |
| Aveanna Healthcare Holdings Inc. | 1.76 Billion USD | 81.994% |
| IMAC Holdings, Inc. | 1.89 Million USD | -16651.249% |
| biote Corp. | 191.84 Million USD | -65.623% |
| Cryo-Cell International, Inc. | 72.25 Million USD | -339.755% |
| Cross Country Healthcare, Inc. | 205.92 Million USD | -54.296% |
| COMPASS Pathways plc | 50.24 Million USD | -532.391% |
| DocGo Inc. | 185.28 Million USD | -71.487% |
| The Ensign Group, Inc. | 2.68 Billion USD | 88.145% |
| Healthcare Services Group, Inc. | 346.56 Million USD | 8.32% |
| InnovAge Holding Corp. | 247.85 Million USD | -28.194% |
| Assure Holdings Corp. | 22.84 Million USD | -1290.573% |
| The Joint Corp. | 62.37 Million USD | -409.358% |
| LifeStance Health Group, Inc. | 804.27 Million USD | 60.495% |
| Mobile-health Network Solutions Class A Ordinary Shares | 3.81 Million USD | -8236.88% |
| ModivCare Inc. | 1.61 Billion USD | 80.278% |
| NewGenIvf Group Limited | 1.24 Million USD | -25493.93% |
| Novo Integrated Sciences, Inc. | 11.06 Million USD | -2771.772% |
| Option Care Health, Inc. | 1.9 Billion USD | 83.336% |
| P3 Health Partners Inc. | 427.3 Million USD | 25.643% |
| P3 Health Partners Inc. | 427.3 Million USD | 25.643% |
| The Pennant Group, Inc. | 394.17 Million USD | 19.393% |
| Surgery Partners, Inc. | 3.65 Billion USD | 91.312% |
| Syra Health Corp. Class A Common Stock | 910.07 Thousand USD | -34812.842% |
| Talkspace, Inc. | 23.57 Million USD | -1247.75% |
| Talkspace, Inc. | 23.57 Million USD | -1247.75% |
| The Oncology Institute, Inc. | 162.39 Million USD | -95.656% |
| The Oncology Institute, Inc. | 162.39 Million USD | -95.656% |